Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC by dual immunotherapy and sorafenib (2024)

Peer-Reviewed Study · Aydın E, Tokat ÜM, Adibi A, Özgü E, Bilgiç ŞN, Demiray M · July 1, 2024

Aydın E et al., 2024-07-01: Case report of a 58-year-old man with heavily pretreated metastatic colon adenocarcinoma who received dual immune checkpoint inhibitors plus mebendazole and lenvatinib, later sorafenib, and achieved a molecular complete response by MRD testing and imaging.

mebendazole was used twice daily at a dose of 100 mg each time.

n/a

Aydın E et al., 2024-07-01: Case report of a 58-year-old man with heavily pretreated metastatic colon adenocarcinoma who received dual immune checkpoint inhibitors plus mebendazole and lenvatinib, later sorafenib, and achieved a molecular complete response by MRD testing and imaging. Study type: case report. N=1. Country: Türkiye (Medicana Health Group, Istanbul). Dose: mebendazole 100 mg orally twice daily. Funder: not stated in the article. Conflicts: the authors state the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Maker: not stated. Comparator: none. Confounded by concurrent dual immunotherapy, lenvatinib and sorafenib; the authors attribute the response to the multi-drug precision-oncology strategy, not to mebendazole alone.